Antibody Sustainability in SARS-CoV-2 Healthcare Professionals’ Patient Cohort; [Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği]

Simple item page
dc.contributor.authorEser E.
dc.contributor.authorŞenol Akar Ş.
dc.contributor.authorAkçali S.
dc.contributor.authorEcemiş T.
dc.contributor.authorErbay Dündar P.
dc.contributor.authorÇiçek K.
dc.contributor.authorAkman D.
dc.contributor.authorTüzün E.
dc.contributor.authorŞanli Erkekoğlu G.
dc.contributor.authorBuran Z.C.
dc.contributor.authorÖztürk Arikan Z.Ö.
dc.contributor.authorKaradağ Yalçin F.
dc.date.accessioned2024-07-22T08:04:29Z
dc.date.available2024-07-22T08:04:29Z
dc.date.issued2022
dc.description.abstractIn this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 ± 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year. © 2022 Ankara Microbiology Society. All rights reserved.
dc.identifier.DOI-ID10.5578/mb.20229807
dc.identifier.issn03749096
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12719
dc.language.isoTurkish
dc.publisherAnkara Microbiology Society
dc.rightsAll Open Access; Gold Open Access
dc.subjectAntibodies, Viral
dc.subjectCOVID-19
dc.subjectDelivery of Health Care
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectSARS-CoV-2
dc.subjectvirus antibody
dc.subjectdiagnosis
dc.subjectfemale
dc.subjecthealth care delivery
dc.subjecthuman
dc.subjectmale
dc.titleAntibody Sustainability in SARS-CoV-2 Healthcare Professionals’ Patient Cohort; [Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu